159 related articles for article (PubMed ID: 19371030)
1. In silico drug screening approach for the design of magic bullets: a successful example with anti-HIV fullerene derivatized amino acids.
Durdagi S; Supuran CT; Strom TA; Doostdar N; Kumar MK; Barron AR; Mavromoustakos T; Papadopoulos MG
J Chem Inf Model; 2009 May; 49(5):1139-43. PubMed ID: 19371030
[TBL] [Abstract][Full Text] [Related]
2. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation.
Friedman SH; Ganapathi PS; Rubin Y; Kenyon GL
J Med Chem; 1998 Jun; 41(13):2424-9. PubMed ID: 9632374
[TBL] [Abstract][Full Text] [Related]
4. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
Durdagi S; Mavromoustakos T; Papadopoulos MG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
[TBL] [Abstract][Full Text] [Related]
5. Receptor- and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, QSAR and molecular docking simulations.
Ahmed L; Rasulev B; Turabekova M; Leszczynska D; Leszczynski J
Org Biomol Chem; 2013 Sep; 11(35):5798-808. PubMed ID: 23900343
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease.
Zhu Z; Schuster DI; Tuckerman ME
Biochemistry; 2003 Feb; 42(5):1326-33. PubMed ID: 12564936
[TBL] [Abstract][Full Text] [Related]
7. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations.
Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
J Comput Chem; 2010 Jan; 31(2):381-92. PubMed ID: 19479738
[TBL] [Abstract][Full Text] [Related]
8. Fullerene-derivatized amino acids: synthesis, characterization, antioxidant properties, and solid-phase peptide synthesis.
Yang J; Alemany LB; Driver J; Hartgerink JD; Barron AR
Chemistry; 2007; 13(9):2530-45. PubMed ID: 17236230
[TBL] [Abstract][Full Text] [Related]
9. Structural and electronic properties of new fullerene derivatives and their possible application as HIV-1 protease inhibitors.
Ibrahim M; Saleh NA; Hameed AJ; Elshemey WM; Elsayed AA
Spectrochim Acta A Mol Biomol Spectrosc; 2010 Feb; 75(2):702-9. PubMed ID: 20044306
[TBL] [Abstract][Full Text] [Related]
10. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
[TBL] [Abstract][Full Text] [Related]
11. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors.
Saleh NA
Spectrochim Acta A Mol Biomol Spectrosc; 2015 Feb; 136 Pt C():1523-9. PubMed ID: 25459714
[TBL] [Abstract][Full Text] [Related]
12. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties.
Frecer V; Berti F; Benedetti F; Miertus S
J Mol Graph Model; 2008 Oct; 27(3):376-87. PubMed ID: 18678515
[TBL] [Abstract][Full Text] [Related]
13. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
14. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance.
Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
Eur J Med Chem; 2010 Apr; 45(4):1387-94. PubMed ID: 20116899
[TBL] [Abstract][Full Text] [Related]
15. Interaction of c(60)-fullerene and carboxyfullerene with proteins: docking and binding site alignment.
Benyamini H; Shulman-Peleg A; Wolfson HJ; Belgorodsky B; Fadeev L; Gozin M
Bioconjug Chem; 2006; 17(2):378-86. PubMed ID: 16536469
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological properties of fullerene-containing amino acids and peptides.
Pantarotto D; Tagmatarchis N; Bianco A; Prato M
Mini Rev Med Chem; 2004 Sep; 4(7):805-14. PubMed ID: 15379647
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
18. Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations.
Tzoupis H; Leonis G; Durdagi S; Mouchlis V; Mavromoustakos T; Papadopoulos MG
J Comput Aided Mol Des; 2011 Oct; 25(10):959-76. PubMed ID: 21969102
[TBL] [Abstract][Full Text] [Related]
19. The use of fullerene substituted phenylalanine amino acid as a passport for peptides through cell membranes.
Yang J; Wang K; Driver J; Yang J; Barron AR
Org Biomol Chem; 2007 Jan; 5(2):260-6. PubMed ID: 17205169
[TBL] [Abstract][Full Text] [Related]
20. Design and activity of cationic fullerene derivatives as inhibitors of acetylcholinesterase.
Pastorin G; Marchesan S; Hoebeke J; Da Ros T; Ehret-Sabatier L; Briand JP; Prato M; Bianco A
Org Biomol Chem; 2006 Jul; 4(13):2556-62. PubMed ID: 16791318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
